CirCode Biomed received U.S. FDA clearance to start a clinical trial testing a circular RNA therapeutic, the company told Endpoints News. The IND greenlight permits CirCode to evaluate safety and early activity of its circular RNA platform in human subjects in the United States, marking a notable regulatory step for an emergent genetic-medicine modality. CirCode will now recruit for the protocol and initiate dosing under FDA supervision, positioning the startup among the first to take circular RNA constructs into human testing.